Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2015

Conditions
OverweightAutism Spectrum Disorder
Interventions
DRUG

Metformin

Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.

DRUG

Placebo

The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.

Trial Locations (4)

15203

University of Pittsburgh Medical Center, Pittsburgh

37212

Vanderbilt University, Nashville

43210

Ohio State University/Nationwide Children's Hospital, Columbus

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Vanderbilt University

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Nationwide Children's Hospital

OTHER

collaborator

Ohio State University

OTHER

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT01825798 - Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) | Biotech Hunter | Biotech Hunter